Brian Goff, Agios Pharmaceuticals CEO

Agios plans tha­lassemia fil­ing in US af­ter un­veil­ing da­ta in trans­fu­sion-de­pen­dent pa­tients

Agios Phar­ma­ceu­ti­cals’ stock $AGIO jumped more than 19% on Mon­day morn­ing af­ter the com­pa­ny an­nounced its oral can­di­date for the blood dis­or­der tha­lassemia re­duced pa­tients’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.